Introduction
Lymphoma, the incidence of which is increasing worldwide, is most often the result of transformed Blymphocytes and includes in a broad range of conditions such as Burkitt's, Hodgkin's and nonHodgkin's lymphoma. In addition, post-transplant lymphoproliferative disease (PTLD), another B-cell condition, comprises a range of hyperplastic to neoplastic lymphoid proliferations (Nalesnik, 1998) . Two essential features of B-cell transformation are cell survival and proliferation, which may be controlled by shared or distinct cellular events (Brennan, 2001) . One of the important elements of B-cell malignancies is the presence of the Epstein-Barr virus (EBV), which can contribute to both of these features.
EBV immortalization of B-cells resulting in the generation of lymphoblastoid cell lines (LCL) is a good model for the cells observed in the polyclonal phase of PTLD (Rickinson and Kie, 1996; Rowe et al., 1998 ). Burkitt's lymphoma (BL) is a fast-growing B-cell lymphoma in which the c-myc translocation is a central feature (Rickinson and Kie, 1996) . While some sporadic BL tumours are EBV negative, greater than 95% of endemic BL are EBV positive (IARC, 1997; Rickinson and Kie, 1996) . However, the role of EBV genes complementing c-myc in BL must dier from that in LCL due to the expression of a distinct pattern of EBV genes. The patterns of EBV gene expression have been classi®ed into dierent types of latency (Rowe et al., 1992) . LCL express ®ve nuclear proteins (EBNA1, 2, 3A, 3B 3C), two membrane proteins (LMP1 and LMP2) as well as RNA transcripts (EBER and BART) . This is termed latency type III. EBV positive BL cells express EBNA1, EBER and BART and this is described as latency type I (Rickinson and Kie, 1996; Rowe et al., 1998) . Therefore LCL, EBV positive BL cells and EBV negative BL cells, each with dierent EBV gene expression, provide three distinct models of B-cell transformation.
One of the key features of PTLD is the production of autocrine growth factors that activate signalling pathways leading to cell growth and survival (Brennan, 2001; Tosato et al., 1998) . Furthermore the EBV genes activate various signalling pathways, for example with LMP1 activates NF-kB (Eliopoulos and Rickinson, 1998) , which has been shown to be essential for LCL survival (Feuillard et al., 2000) . However, the importance of other signalling pathways in B-cell transformation has not been well characterized. Recently, phosphatidylinositol 3-kinase (PI3K), a lipid kinase activated by cytokines (Vanhaesebroeck and Alessi, 2000) , has been implicated both in lymphocyte growth and survival (Ahmed et al., 1997; Brennan et al., 1997; Craddock et al., 1999; Fruman et al., 1999; Hinton and Welham, 1999; Pogue et al., 2000; Suzuki et al., 1999) . In particular, two reports have produced con¯icting evidence for the importance of PI3K for murine B-cell survival (Ahmed et al., 1997; Hinton and Welham, 1999) . The introduction of a dominant inhibitory PI3K into murine B-cells inhibited cell growth but had very little eect on cell survival (Craddock et al., 1999) whereas an older report suggested that the PI3K eector, Akt, could prevent cell apoptosis (Ahmed et al., 1997) . Furthermore, Bcells from mice de®cient in one subunit of PI3K show reduced proliferation (Fruman et al., 1999; Suzuki et al., 1999) . These observations suggest that PI3K may play a role in the immortalization during B-cell transformation, a hypothesis that needs to be tested in human B-lymphocytes.
This study was initiated to probe the role of PI3K in immortalized B-lymphocytes. B-cells from EBV negative Burkitt's lymphoma died rapidly following treatment with a PI3K inhibitor, LY294002 while those expressing EBV latent genes and LCL survived but were growth inhibited. This growth inhibition paralleled the loss of the G1 cyclins, cyclin D2 and cyclin D3, an accumulation of p27kip1, a cyclin dependent kinase inhibitor and a decrease in phosphorylation of members of the pocket protein family. Furthermore an active form of PI3K promotes E2F transcriptional activity, a key transcription factor at G1 to S phase transition. These data suggest a mechanism by which PI3K may play a role in B-cell tumour immortalization.
Results

Effects of inhibition of PI3K on B-cell survival
PI3K has been implicated in the growth and survival of a range of cell types. However its eects on cell lines from B-cell tumours have not been analysed in detail. This study was initiated to determine the role that PI3K played in growth and survival of immortalized Bcells, as both of these processes have been shown to be important in malignancy. The ®rst step was to characterize the eects of a speci®c PI3K inhibitor, LY294002 (Blommaart et al., 1997) , on cell survival. LY294002 was chosen for these experiments as it is stable in media and has a much longer half life than wortmannin, another PI3K inhibitor. Five B-cell lines were treated with 5 mM or 10 mM LY294002 for 24 h, and cell survival was assayed by exclusion of propidium iodide (PI) by FACS. Figure 1 shows the percentage of cells unable to exclude PI following the treatment with LY294002. These cell lines were BL41, Mutu I, Mutu III, Cor LCL and Jurkat. BL41 and Mutu are Burkitt lymphoma cell lines. BL41 is negative for Epstein-Barr virus (EBV) whereas Mutu is EBV positive. The Mutu I clone shows a latency I pattern of EBV gene expression, EBNA1, EBERs and BARTs, as observed in the original tumour in vivo. The Mutu III clone has become activated in vitro, and expresses all the EBV latent genes, EBNA1, 2, 3A, 3B, 3C and LMP1 and LMP2 as well as EBERs and BARTs. Cor LCL is an EBV immortalized lymphoblastoid cell line derived from normal human B-cells. Similarly to the Mutu III tumour line, the Cor-LCL express all the EBV latent genes. Jurkat is an EBV-negative Tlymphoma cell line and was included as a control, being a cell line that does not die following treatment with LY294002. Figure 1 shows that 10 mM LY294002 induced cell death in BL41 and Mutu I, the Burkitt lymphoma cell lines. A lower concentration, 5 mM, also causes cell death in BL41 and some cell death in Mutu I, albeit at a reduced level. Neither Mutu III nor Cor LCL exhibited LY294002-induced cell death, suggesting that one or more of the EBV latent genes generated a survival signal that could overcome the loss of PI3K activity.
LY294002 inhibits the growth of EBV immortalized B-cells
The rapid death, within 24 h, of the BL41 and Mutu I Burkitt's lymphoma cells prevented any long-term analysis of eects of LY294002, the PI3K inhibitor. However, Mutu III cells, which did not die rapidly, were treated with a range of concentrations of LY294002 for up to 72 h. The cell number and the ability of the cells to exclude propidium iodide was measured by FACS. Figure 2a shows the eects of two doses of LY294002 on the growth of Mutu III cells. Both 1 mM and 10 mM of LY294002 inhibited cell growth but had very little eect on cell viability ( Figure  2b ). A comparison of the eects of a range of concentrations of LY294002, after 72 h treatment, shows a clear dierence between the dose that aects cell proliferation and the dose that aects cell viability ( Figure 2c ).
While Mutu III cells are a Burkitt's lymphoma line, they express the same set of EBV latent genes as Cor LCL. Neither cell line died following short-term treatment with LY294002. For this reason we tested Figure 1 Eects of LY294002, a PI3K inhibitor, on cell death. Various B-cell lines, as indicated, and Jurkat cells as a control, were treated with two doses of LY294002, as indicated, for 24 h and cell death was determined by the entry of propidium iodide into the cells, which was assayed by FACS the eects of LY294002 on the proliferation of Cor LCL. The cells were incubated with ®ve doses of LY294002 for 4 days and the number of viable cell remaining were counted ( Figure 3a) . Figure 3a shows a dose responsive decrease in cell number following treatment of Cor LCL with LY294002. Cell viability was not aected. PI3K signals to a diverse range of eector molecules, one of which is protein kinase B (PKB), also called Akt. PI3K regulates the phosphorylation of PKB. To show the ecacy of LY294002, as a PI3K inhibitor in Cor LCL, the eects on the phosphorylation of PKB was determined using phosphospeci®c antibodies. Figure 3b shows that LY294002 inhibits a constitutive phosphorylation of PKB that occurs in Cor LCL. A pan-PKB antibody was used to demonstrate equal protein loading (Figure 3b ). These data illustrate that LY294002 was eective at inhibiting PI3K mediated pathways at the doses that were eective at inhibiting cell growth. Four other lymphoblastoid cell lines, the long-established IB4 LCL and three other freshly generated LCL, were treated with LY294002 and a similar inhibition of growth was seen in all cases (data not shown).
Cell growth requires the ordered progression through the cell cycle from G1 phase through to S phase, where DNA synthesis occurs, to a second waiting phase, called G2 and ®nally to cell division during M phase. The position of cells in the cell cycle can be determined by ®xation and analysis of the amount of DNA contained in the cells using PI and FACS analysis. The position of Cor LCL in the cell cycle was analysed following treatment of the cells with LY294002. Figure  4 shows the eects of treating Cor LCL with three doses of LY294002 for 24 h. The FACS pro®les show a clear dierence between control cells and those treated with 20 mM LY294002. The number of cells in each phase of the cycle was determined and the results are shown in graph format. Increasing concentrations of LY294002 causes an accumulation of the cells in G1 phase of the cell cycle and a loss of cells in other phases of the cell cycle after 24 h. Similar results were seen in IB4 LCL (data not shown). This suggests that a PI3K signal is required for B-cells to transit from G1 into the cell cycle.
PI3K regulates E2F, a cell cycle transcription factor, in lymphoblastoid cells PI3K has been previously shown to activate E2F transcriptional activity in a T-lymphocytes model (Brennan et al., 1997) . E2F is a transcription factor that is active during the G1 phase of the cell cycle and is essential for G1 to S phase transition. It is involved in the induction of the genes required for DNA synthesis such as dihydrofolate reductase and genes important for cell cycle regulation such as cyclin E. Both Cor LCL and IB4 LCL can be transfected, albeit at low transfection eciencies. This allowed the investigation of the requirement for PI3K in the regulation of E2F transcriptional activity. IB4 LCL ( Figure 5a ) and Cor LCL ( Figure 5b ) were transfected with a reporter for E2F, which contains two copies of the E2F binding site upstream of a chloramphenicol acetyl transferase (CAT) gene. LY294002 inhibited E2F transcriptional activity in both cell lines. The doses of LY294002 used in these experiments paralleled the eects on the cell cycle.
The E2F reporter was also used to monitor the eect of an active form of PI3K. The CD2p110 protein is an active PI3K mutant in which the catalytic subunit of PI3K is fused to the extracellular and transmembrane portion of rat CD2 (Reif et al., 1996) . There is also a kinase dead mutant, CD2p110KD, which has a point mutation in its catalytic domain (Reif et al., 1996) . CD2p110 and CD2p110KD were transfected into IB4 LCL with the E2F reporter (Figure 5c ). The results shows that CD2p110 could increase E2F transcriptional activity while the kinase dead mutant (CD2p110KD) could not. Expression of both proteins was con®rmed by Western blotting (data not shown). Figure 5d shows the eects of CD2p110 on the E2F reporter construct in Cor LCL. In both IB4 LCL and Cor LCL the eect of CD2p110 was dose responsive. The introduction of an expression vector encoding an active mutant of PKB, a PI3K eector, could also increase E2F transcriptional activity to a similar level seen by the introduction of CD2p110 (data not shown). However this mutant may activate pathways not activated by PKB in these LCL, so this result must be interpreted conservatively. These data supports a role for PI3K in the transition from G1 to S phase of the cell cycle and thus a role in B-lymphocyte proliferation.
Treatment with LY294002 leads to a loss of D-type cyclins E2F transcriptional activity is regulated by the family of pocket proteins, the prototypic member of which is pRb (Sherr, 1996) . The pocket proteins are phosphorylated Figure 4 Inhibition of PI3K causes an accumulation in G1 phase of the cell cycle. Cor LCL were treated with LY294002, a PI3K inhibitor, at the concentrations indicated for 24 h. The position of the cells in the cell cycle was determined by FACS using propidium iodide DNA staining in the G1 phase of the cell cycle which leads to the release of E2F and an increase in its transcriptional activity (Sherr, 1996) . Since inhibition of PI3K caused an accumulation of cells in G1 phase and prevented E2F transcriptional activity, the eect of LY294002 on both of the D-type cyclins was investigated. B-lymphocytes express cyclin D2 and cyclin D3 but do not express cyclin D1 (Palmero et al., 1993) . Therefore, the eects of LY294002 on these cyclins were investigated in Cor LCL and IB4 LCL. Figure 6a illustrates the results from Cor LCL and it can be seen that D-type cyclin levels are reduced in a dose responsive fashion following treatment with LY294002. In EBV immortalized cells, both EBNA2A and LMP1 have been postulated to play a role in the induction of D-type cyclins in EBV immortalized cells (Arvanitakis et al., 1995; Sinclair et al., 1994) . We investigated the eects of LY294002 on the expression of LMP1 and EBNA2A (Figure 6b ) in the same samples as those assayed for cyclin D2 and cyclin D3. Expression of these EBV expressed proteins was not downregulated by LY294002, suggesting that PI3K may co-operate with these EBV encoded genes to regulated D-type cyclin expression and thus the growth of B-lymphocytes.
Figure 5 PI3K controls E2F transcriptional activity. IB4 LCL (a) and Cor LCL (b) were transfected with a reporter for E2F transcriptional activity, a transcription factor essential for G1 to S phase cell cycle progression. They were then treated with LY294002 at the doses indicated. After 24 h cells were harvested and chloramphenicol acetyl transferase reporter activity was determined using a radioactive assay. IB4 LCL (c) and Cor LCL (d) were transfected with a reporter for E2F transcriptional activity together with various amounts of an expression vector for an active form of PI3K, CD2p110 or a kinase dead form of the mutant (CD2p110KD). After 24 h cells were harvested and chloramphenicol acetyl transferase reporter activity was determined using a radioactive assay Figure 6 (a) PI3K regulates the expression of D-type cyclins in Cor LCL. Cor LCL were treated with LY294002 for 24 and 48 h. They were then harvested and processed for SDS ± PAGE and Western blotting. D-type cyclins were analysed using speci®c antibodies. (b) Expression of the EBV latent genes, LMP-1 and EBNA-2A is not aected by LY294002. Cor LCL were treated with LY294002 for 24 h. They were then harvested and processed for SDS ± PAGE and Western blotting. LMP-1 and EBNA-2A were analysed using speci®c antibodies Two newly established LCL, denoted LCL-1 and LCL-2, were also tested for the eects of LY294002 on cell cycle proteins. The entry of these lymphoblastoid cell lines into cell cycle is also inhibited by the PI3K inhibitor (data not shown). Figure 7 shows the eects on cyclin D2, cyclin D3, the cyclin dependent kinase inhibitor, p27kip1 and the pocket proteins pRb and p107. Treatment with LY294002, results in a loss of cyclin D2 and cyclin D3, similar to that seen in Cor LCL. A converse increase in the levels of the cyclin dependent kinase inhibitor, p27kipl is observed. Together D-type cyclins and the cyclin dependent kinase inhibitors regulate the cyclin dependent kinase 4 and 6. The most important substrate of the cyclin dependent kinase 4 and 6 are the pocket proteins of which pRb is the prototypic member. Figure 7 also shows a clear loss in the bands corresponding to the phosphorylated forms of pRb. There are multiple phosphorylation sites on pRb and the cumulative phosphorylation causes pRb to be detected as a higher mobility form than when it is unphosphorylated. This is best illustrated by comparing the ®nal lane, which contains predominantly unphosphorylated pRb and the ®rst lane in which pRb is predominantly phosphorylated. Interestingly no change was observed in the pocket protein, p130 (not shown), but a decrease in the phosphorylation of p107 was observed (Figure 7) . It is the unphosphorylated pocket proteins that binds to E2F and resulting in a repressive DNA binding complex that prevents the expression of genes required for the cell cycle.
Discussion
This study indicates that in immortalized B-cells, PI3K can play a role in both cell survival and proliferation. It is dicult to separate the eects of PI3K on cell cycle from those of proliferation when cells die following treatment with PI3K inhibitors. However with EBV immortalized cells, LY294002 does not cause cell death but rather leads to a reduction in cell growth. This reduction in cell growth is the result of an accumulation of the cells in G1 phase of the cell cycle that is likely to be due to the loss of D-type cyclins. An active form of PI3K, CD2p110, results in an increase of E2F transcriptional activity, a key event in G1 to S phase transition. The inhibition of the cell cycle parallels the loss of D-type cyclin expression. Together these data identify PI3K as a key regulator of cell cycle in B-lymphocytes.
The role of PI3K in lymphocyte survival is somewhat controversial. This study demonstrates that the cell type used can aect the results obtained. Our data show clearly that some B-cells are extremely sensitive to LY294002 whereas other B-cells are very resistant. In the case of Burkitt's lymphoma cell lines, PI3K plays a critical role in cell survival. An essential feature of BL-cells is the myc translocation, which drives apoptosis in BL-cells (Milner et al., 1993) . PI3K has been shown to suppress c-myc induced apoptosis (Kaumann-Zeh et al., 1997) and a more recent study suggests that PI3K can provide a survival signal for murine B-lymphocytes expressing high levels of c-myc (Carey and Scott, 2001 ). In Mutu III cells, a BL line that expresses all the EBV latent genes, the levels c-myc expression are reduced (Floettmann et al., 1996) . Furthermore LMP1, an EBV latent gene, causes an increase in the expression of antiapoptotic genes such as bcl-2 and b¯-1 (D'Souza et al., 2000; Henderson et al., 1991) . In Mutu III cells the inhibition of PI3K causes substantially less cell death (Figure 3 ) particularly when compared to Mutu I (Figure 1 ) which only express latency type I. The requirement for PI3K most likely re¯ects the sensitivity of the cell to death signalling and the balance of pro-apoptotic and antiapoptotic molecules that are present in the cell.
The role of PI3K in human B-lymphocyte growth has strong parallels with observations in mouse cells and human T-lymphocytes (Brennan et al., 1997; Carey and Scott, 2001; Craddock et al., 1999) . In a mouse Bcell line, Baf 3, the introduction of a dominant inhibitory PI3K inhibits cell growth but not cell survival (Craddock et al., 1999) . Also, in mice de®cient in the adaptor subunit of PI3K, B-cell growth is inhibited (Fruman et al., 1999; Suzuki et al., 1999) . The present data suggests more than one molecular mechanism for the interaction of PI3K with the cell cycle machinery. In human T-lymphocytes, we have evidence that PI3K plays a role in D-type cyclin transcription and translation (manuscript in preparation). It is likely that a similar mechanism occurs in immortalized B-cells. Both LMP1 and EBNA-2 have been shown to play a role in the regulation of cyclin D2 (Arvanitakis et al., 1995; Sinclair et al., 1994) . However, in this study the expression of these proteins were unchanged while cyclin D2 expression was inhibited by LY294002. The eects of EBNA-2 have been shown to be indirect (Spender et al., 2001) . This raises the possibility that EBNA-2 could work through PI3K. It is also possible that LMP1, EBNA2 and PI3K act independently to regulate D-type cyclins. The Figure 7 PI3K regulates cell cycle proteins in two other lymphoblastoid cell lines. Two lymphoblastoid cell lines (LCL-1 and LCL-2) were treated with LY294002 for 48 h. They were then harvested and processed for SDS ± PAGE and Western blotting. D-type cyclins, p27kip1 and the pocket proteins pRb and p107 were detected using speci®c antibodies accumulation of p27kip1 in cells treated with LY294002 also parallels other cell systems (Brennan et al., 1997; Dijkers et al., 2000; Taylor et al., 2000) . PI3K has been shown to play a role in the down regulation of p27kip1 by both transcriptional and posttranscriptional mechanisms (Dijkers et al., 2000; Nourse et al., 1994; Pagano et al., 1995) . The mechanisms important in LCL remain to be characterized.
The question of what leads to an active PI3K in EBV immortalized cells is an interesting one. Recent publications suggest that LMP2A activates PKB via PI3K (Scholle et al., 2000; Swart et al., 2000) and this may play a role cell survival. Also, a number of cytokines that have been shown to be expressed by EBV immortalized cells such as interleukin-10 and interleukin-6 (Tosato et al., 1998) are capable of activating PI3K (Chung et al., 2000; Crawley et al., 1996) . It is likely that multiple mechanisms are utilized to provide an optimal PI3K activity required for cell growth. As IL-10 and IL-6 also play a role in the spontaneous growth of Kaposi's sarcoma herpesvirusassociated infection primary eusion lymphoma cells (Jones et al., 1999) , it is possible that PI3K may play role in the growth of these cells as well.
The contribution of PI3K to B-cell growth and survival raises the possibility that molecules that control the activity of PI3K, or molecules in PI3K mediated pathways, may be mutated in lymphoma. One candidate molecule is the lipid phosphatase, PTEN. PTEN degrades the lipids generated by PI3K (Gold et al., 2000) . The PTEN gene has been shown to be altered in some non-Hodgkin's lymphomas (Butler et al., 1999) and lymphoid neoplasms (Sakai et al., 1998) . Furthermore, mice with a mutated PTEN gene shown increased susceptibility to lymphomas (Suzuki et al., 1998) . It is also interesting that a constitutively active PI3K has been found in a lymphoma (Jimenez et al., 1998) and that the PI3K eector, PKB, was ®rst identi®ed from a lymphoma (Staal and Hartley, 1988) . Together these observations suggest the pathways activated by PI3K play an important role in lymphocyte immortalization and malignancy and may have a diagnostic or prognostic relevance in leukaemia and lymphoma.
Materials and methods
Cell culture and reagents
Mutu I and Mutu III (Gregory et al., 1990) , BL41 (Rowe et al., 1986) , Cor LCL, an spontaneous LCL from the blood of a healthy donor (Fais et al., 1996) , and IB4 LCL, an LCL generated from cord blood B-cells immortalized with B95.8 EBV (Sample and Kie, 1990) , were all maintained in RPMI media in a 5% CO 2 humidi®ed incubator. [ 14 C]Acetyl coenzyme A (at 50 mCi/mmol) was from Amersham Corporation. Antibodies for cyclin D2 (M20), and p107 are from Santa Cruz Biotechnology. Antibodies for cyclin D3 (DCS22) were a gift from Dr G Peters (ICRF). Antibodies against rat CD2 (OX34) (Williams et al., 1987) , LMP1 (CS1 ± 4) (Rowe et al., 1987) , EBNA2A (PE-2) were prepared from hybridomas grown in the laboratory. PKB antibodies were supplied by Cell Signalling Technologies. Antibodies to pRb were supplied by BD Pharmingen.
Counting and cell cycle analysis
Cells were counted by measuring the number of events of the correct forward and side scatter that excluded propidium iodide, and which passed through the FACS during a constant time. Cell cycle analysis was performed by FACS (Griths et al., 1999) . Cells were ®xed in 70% ethanol for at least 30 min at 48C. The ethanol was removed and cells were washed in PBS. The cells were incubated in 1 mg/ml RNase A for 15 min and then stained with 50 g/ml propidium iodide. Data was aquired in a Becton Dickinson FASCaliber and doublet discrimination was performed.
Plasmids, transfection and CAT assay E2ACAT, originally described by Murthy et al. (1985) is comprised of 7284 bp to +62 of the E2A promoter upstream of a CAT gene. Two E2F binding sites are present in E2A CAT (the ®rst is between 729 and 721 and the second is between 782 and 766), and they allow the E2A promoter to report and sensitively quantitate E2F transcriptional activity (Brennan et al., 1997 (Brennan et al., , 1999 Mann and Jones, 1996) . The plasmid encoding the active PI3K (CD2p110) has been described previously (Reif et al., 1996) . Plasmid DNA was puri®ed by caesium chloride density gradient centrifugation. Electroporation of 15610 6 lymphoblastoid cells in 0.5 ml of RPMI, supplemented with 10% FCS, was carried out at room temperature with a Gene Pulser (BioRad), set at 280 V, 950 mFD. After transfection, cells were replaced in culture for 16 ± 18 h prior to lysis. Cells were lysed in buer containing 10 mM Tris (pH 8.0), 1 mM EDTA, 150 mM NaCl, 0.65% NP40 then assayed for CAT activity by radioisotope method (Genot et al., 1995) .
Western blotting
Samples were lysed in 100 ml of 26gel sample buer (0.1 M Tris buer pH 6.8, 0.2 M dithiothreitol, 4% sodium dodecyle sulphate, 20% glycerol, 0.1% bromophenol blue). DNA was sheared by sonication and the samples were boiled for 5 min. Samples were clari®ed by centrifugation at 13 000 g for 5 min. The solubilized proteins were separated by SDS ± polyacrylamide gel electrophoresis and transferred to PVDF membranes for immunoblotting using an alkaline phosphatase chemiluminescent detection protocol (Rowe and Jones, 2001) . Typically, the lysates from 2610 5 cells were applied to each track of the gel. All primary antibody incubations were for 90 min at room temperature. Antibodies were used at the following concentrations: cyclin D2, 0.2 mg/ml; cyclin D3, 1.8 mg/ml; OX34, 4.3 mg/ml; LMP1 (CS1 ± 4), 1 mg/ml each; PE-2, 0.5 mg/ml; p27kipl, 0.2 mg/ml; pRb, 0.5 mg/ml; p107, 0.2 mg/ml; PKB and phosphospeci®c PKB, 1/1000 dilution. Secondary antibody, alkaline phosphatase conjugated, were incubated for 1 h.
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